Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer

OBJECTIVES: The purpose of this study was to determine the relationship between carbohydrate antigen (CA) 19-9 levels and outcome in patients with borderline resectable pancreatic cancer treated with neoadjuvant therapy (NT). METHODS: This study included all patients with borderline resectable pancr...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Tzeng, Ching-Wei D, Balachandran, Aparna, Ahmad, Mediha, Lee, Jeffrey E, Krishnan, Sunil, Wang, Huamin, Crane, Christopher H, Wolff, Robert A, Varadhachary, Gauri R, Pisters, Peter W T, Aloia, Thomas A, Vauthey, Jean-Nicolas, Fleming, Jason B, Katz, Matthew H G
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Blackwell Publishing Ltd 2014
Pynciau:
Research Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4008161/
https://ncbi.nlm.nih.gov/pubmed/23991810
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/hpb.12154
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg